Drug Search Results
More Filters [+]

OSI-461

Alternative Names: osi-461, cp-461, cp461, cp 461, osi461, osi 461
Latest Update: 2011-10-17
Latest Update Note: Clinical Trial Update

Product Description

OSI Pharmaceuticals is developing OSI-461, a potent analog of exisulind, for the potential treatment of cancer and inflammatory bowel disease. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/15242254/)

Mechanisms of Action: cGAMP Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Astellas Pharma
Company Location: NEW YORK NY 10005
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for OSI-461

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Melanoma|Prostate Cancer|Renal Cell Carcinoma|Chronic Lymphoid Leukemia|Crohn Disease|Lymphocytic Chronic B-Cell Leukemia

Phase 1: Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

OSI-461-010

P1

Completed

Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia

None

OSI-461-013

P2

Terminated

Melanoma

None

OSI-461-006

P2

Completed

Prostate Cancer

None

OSI-461-003

P2

Completed

Renal Cell Carcinoma

None

Recent News Events

Date

Type

Title